Hematologic Oncology
Shanghai Yingli Pharmaceutical Co. Ltd. is involved in clinical research for relapsed or refractory peripheral T/NK cell lymphoma, with a specific focus on peripheral T-cell lymphoma and related aggressive lymphoid malignancies.
- Peripheral T/NK Cell Lymphoma
- Relapsed or Refractory Disease
- Lymphoid Neoplasms
The sponsor’s research activity centers on treatment options for patients with difficult-to-treat hematologic cancers in the oncology setting.
Cutaneous T-Cell Lymphoma
The company also supports research in cutaneous T-cell lymphoma, addressing a rare skin-based T-cell malignancy that requires targeted therapeutic strategies.
- Cutaneous T-Cell Lymphoma
- Skin Lymphoma
- T-Cell Malignancy
This area reflects interest in therapies for advanced lymphoma subtypes with limited treatment options.
Targeted Oncology Therapy
Research funded by the sponsor includes investigation of linperlisib, indicating a therapeutic focus on targeted treatment approaches in oncology.
- Linperlisib
- Targeted Therapy
- Antineoplastic Agents
The sponsor’s portfolio shows involvement in therapies designed to address lymphoma biology through molecularly directed treatment concepts.
